Naltrexone-induced dysphoria in former opioid addicts - PubMed (original) (raw)
Clinical Trial
. 1985 Sep;142(9):1081-4.
doi: 10.1176/ajp.142.9.1081.
- PMID: 2992300
- DOI: 10.1176/ajp.142.9.1081
Clinical Trial
Naltrexone-induced dysphoria in former opioid addicts
T J Crowley et al. Am J Psychiatry. 1985 Sep.
Abstract
Naltrexone treatment, used to prevent relapse among former opioid addicts, is reported to have an extraordinary rate of noncompliance. Since activation of opioid receptors produces a sense of well-being, naltrexone's blockade of these receptors might produce dysphoria, which could contribute to noncompliance among addicts under treatment. To test this hypothesis, the authors administered naltrexone to four men who had been free of opioids for 9 to 44 months using a 6-week, placebo-controlled crossover design. One subject dropped out with abstinence-like symptoms, and two others reported mild but significantly greater dysphoria during naltrexone administration. The results suggest that naltrexone may induce mild dysphoria long after addicts stop using opioids.
Similar articles
- Clinical experience with naltrexone in suburban opioid addicts.
Tennant FS Jr, Rawson RA, Cohen AJ, Mann A. Tennant FS Jr, et al. J Clin Psychiatry. 1984 Sep;45(9 Pt 2):42-5. J Clin Psychiatry. 1984. PMID: 6469935 - Review of naltrexone, a long-acting opiate antagonist.
Crabtree BL. Crabtree BL. Clin Pharm. 1984 May-Jun;3(3):273-80. Clin Pharm. 1984. PMID: 6329589 Review. - Effects of naltrexone on mood and neuroendocrine function in normal adult males.
Mendelson JH, Ellingboe J, Keuhnle JC, Mello NK. Mendelson JH, et al. Psychoneuroendocrinology. 1978 Oct;3(3-4):231-6. doi: 10.1016/0306-4530(78)90013-6. Psychoneuroendocrinology. 1978. PMID: 219434 Clinical Trial. No abstract available. - The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.
Schecter A. Schecter A. Am J Drug Alcohol Abuse. 1980;7(1):1-18. doi: 10.3109/00952998009028406. Am J Drug Alcohol Abuse. 1980. PMID: 6254356 Review. No abstract available. - Abstinence treatments for opiate addicts: therapeutic community or naltrexone?
Arndt I, McLellan AT, O'Brien CP. Arndt I, et al. NIDA Res Monogr. 1984 Mar;49:275-81. NIDA Res Monogr. 1984. PMID: 6434972 No abstract available.
Cited by
- Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.
Gonzalez JP, Brogden RN. Gonzalez JP, et al. Drugs. 1988 Mar;35(3):192-213. doi: 10.2165/00003495-198835030-00002. Drugs. 1988. PMID: 2836152 Review. - Dopamine D2/3- and μ-opioid receptor antagonists reduce cue-induced responding and reward impulsivity in humans.
Weber SC, Beck-Schimmer B, Kajdi ME, Müller D, Tobler PN, Quednow BB. Weber SC, et al. Transl Psychiatry. 2016 Jul 5;6(7):e850. doi: 10.1038/tp.2016.113. Transl Psychiatry. 2016. PMID: 27378550 Free PMC article. Clinical Trial. - Improving clinical outcomes for naltrexone as a management of problem alcohol use.
Hulse GK. Hulse GK. Br J Clin Pharmacol. 2013 Nov;76(5):632-41. doi: 10.1111/j.1365-2125.2012.04452.x. Br J Clin Pharmacol. 2013. PMID: 22946873 Free PMC article. Review. - Behavioral architecture of opioid reward and aversion in C57BL/6 substrains.
Kirkpatrick SL, Bryant CD. Kirkpatrick SL, et al. Front Behav Neurosci. 2015 Jan 12;8:450. doi: 10.3389/fnbeh.2014.00450. eCollection 2014. Front Behav Neurosci. 2015. PMID: 25628547 Free PMC article. - Opioid dependence treatment: options in pharmacotherapy.
Stotts AL, Dodrill CL, Kosten TR. Stotts AL, et al. Expert Opin Pharmacother. 2009 Aug;10(11):1727-40. doi: 10.1517/14656560903037168. Expert Opin Pharmacother. 2009. PMID: 19538000 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical